论文部分内容阅读
近年来,恶性肿瘤的放射治疗正在迅速推广应用,各种类型的放射源如X射线、β射线、中子射线等也正在抗肿瘤领域内发挥越来越大的作用。但随着放射治疗的推广应用,由放射引起的副反应如胃肠道反应,皮肤反应等就成为能否完成疗程的一个重要问题。根据1969年美国陆军医疗部门的报告标题药物(WR-2721)对小鼠在绝对放射致死剂量下存活率为100％。1971年Yuhas等报道了WR-2721保护正常细胞避免放射伤害的程度大大高于保护肿瘤细胞。用药后动物正常细胞的抗放作用增加近一倍,而肿瘤细胞则基本上维持不变。由于WR-2721辐射防护效价高,毒性低,对中子的损伤也有一定的防护作用,国外已应用于临床,被认
In recent years, the radiotherapy of malignant tumors is rapidly being popularized and applied. Various types of radioactive sources such as X-ray, β-ray and neutron radiation are playing an increasingly important role in the field of anti-tumor. However, with the promotion and application of radiation therapy, side effects caused by radiation, such as gastrointestinal reactions and skin reactions, have become an important issue for whether or not to complete the treatment. According to the report of the U.S. Army Medical Department in 1969, the title drug (WR-2721) had a 100% survival rate on mice at absolute radiotoxic doses. In 1971, Yuhas et al. Reported that WR-2721 protects normal cells to a much greater extent than radiation to protect the tumor cells. Antibiotics of normal animal cells nearly doubled after treatment, while the tumor cells remained basically unchanged. WR-2721 radiation protection as a high potency, low toxicity, damage to neutrons also have a protective effect, has been applied abroad in clinical, was identified